This was a non-interventional, secondary use of data, retrospective, cohort study. The data extracted in this study was used as secondary use of collected patient information in the database, Japan Medical Data Survey (JAMDAS), owned by M3 Inc. (Tokyo, Japan). JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of medical institutions, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities etc.
Study Type
OBSERVATIONAL
Enrollment
40,563
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Number of Adverse Events (AEs) From Initiation of Antihypertensive Treatment to Weeks 8 and 24 Categorized by Type of AE
Time frame: Week 8 and Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Weeks 8 and 24 Categorized by Type of AE
Time frame: Week 8 and Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Weeks 8 and 24 Categorized by Type of AE
Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 8 and Week 24
Number of Adverse Events (AEs) From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Blood Pressure (BP) Category
BP Categories included Grade I, II, III, and (isolated) systolic hypertension.
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per BP Category
BP Categories included Grade I, II, III, and (isolated) systolic hypertension.
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per BP Category
BP Categories included Grade I, II, III, and (isolated) systolic hypertension. Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Age Group Category
Age group categories: * Less than 65 years old * 65 to 74 years old * 75 years or older
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Age Group Category
Age group categories: * Less than 65 years old * 65 to 74 years old * 75 years or older
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Age Group Category
Age group categories: * Less than 65 years old * 65 to 74 years old * 75 years or older Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Body Mass Index (BMI) Category
BMI categories: * BMI \<18.5 * 18.5 ≤ BMI \<25 * 25 ≤ BMI
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per BMI Category
BMI categories: * BMI \<18.5 * 18.5 ≤ BMI \<25 * 25 ≤ BMI
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per BMI Category
BMI categories: * BMI \<18.5 * 18.5 ≤ BMI \<25 * 25 ≤ BMI Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Estimated Glomerular Filtration Rate (eGFR) Category
eGFR categories: * eGFR \<30 * 30 ≤ eGFR \<60 * 60 ≤ eGFR
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per eGFR Category
eGFR categories: * eGFR \<30 * 30 ≤ eGFR \<60 * 60 ≤ eGFR
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per eGFR Category
eGFR categories: * eGFR \<30 * 30 ≤ eGFR \<60 * 60 ≤ eGFR Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Potassium Level
Potassium (K) levels: * K \<3.5 * 3.5 ≤ K \<5.5 * 5.5 ≤ K
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Potassium Level
Potassium (K) levels: * K \<3.5 * 3.5 ≤ K \<5.5 * 5.5 ≤ K
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Potassium Level
Potassium (K) levels: * K \<3.5 * 3.5 ≤ K \<5.5 * 5.5 ≤ K Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Creatinine Level
Creatinine (Cr) Levels: * Cr \<1.5 * 1.5 ≤ Cr
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Creatinine Level
Creatinine (Cr) Levels: * Cr \<1.5 * 1.5 ≤ Cr
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Creatinine Level
Creatinine (Cr) Levels: * Cr \<1.5 * 1.5 ≤ Cr Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Proteinuria
Proteinuria: * Urine protein \<30: Negative * 30 ≤ Protein urine: Positive
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Proteinuria
Proteinuria: * Urine protein \<30: Negative * 30 ≤ Protein urine: Positive
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE by Proteinuria
Proteinuria: * Urine protein \<30: Negative * 30 ≤ Protein urine: Positive Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Number of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Class of Antihypertensive Medication
Antihypertensive medication classes included calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and diuretics.
Time frame: Week 24
Number of Patients With AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Class of Antihypertensive Medication
Antihypertensive medication classes included CCBs, ACE inhibitors, ARBs, and diuretics.
Time frame: Week 24
Incidence Rate of AEs From Initiation of Antihypertensive Treatment to Week 24 Categorized by Type of AE per Class of Antihypertensive Medication
Antihypertensive medication classes included CCBs, ACE inhibitors, ARBs, and diuretics. Incidence rate was calculated by dividing the number of patients who had an event by the total number of patients.
Time frame: Week 24
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by BP Category
BP categories included Grade I, II, and III hypertension.
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by Age Group Category
Age group categories: * Less than 65 years old * 65 to 74 years old * 75 years or older
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by BMI Category
BMI categories: * BMI \<18.5 * 18.5 ≤ BMI \<25 * 25 ≤ BMI
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by eGFR Category
eGFR categories: * eGFR \<30 * 30 ≤ eGFR \<60 * 60 ≤ eGFR
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by Potassium Level
Potassium (K) levels: * K \<3.5 * 3.5 ≤ K \<5.5 * 5.5 ≤ K
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by Creatinine Level
Creatinine (Cr) Levels: * Cr \<1.5 * 1.5 ≤ Cr
Time frame: Weeks 4, 8, and 12
Change in BP From Initiation of Antihypertensive Treatment to Weeks 4, 8, and 12 by Proteinuria
Proteinuria: * Urine protein \<30: Negative * 30 ≤ Protein urine: Positive
Time frame: Weeks 4, 8, and 12
Number of Patients who Achieved the BP Goal at Last Visit Categorized by Subgroup
The BP goal was 130/80 millimeters of mercury (mm Hg). Subgroups: * BP Grade * Age * BMI * Estimated glomerular filtration rate (eGFR) * Potassium Level * Creatinine Level * Proteinuria (positive or negative)
Time frame: Up to 13 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.